Shots:

• The P-III PANTHER trial evaluates pevonedistat + azacitidine vs azacitidine alone in patients with higher-risk MDS- CMML and AML
• The study did not achieve its pre-defined 1EPs of EFS- the safety profile was consistent with previously reported data of the combination regimen
• Pevonedistat is an NAE inhibitor that leads to cancer cell death by disrupting protein homeostasis. Additionally- the results will be submitted for presentation at an upcoming medical congress

Ref: Takeda | Image: Takeda